WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 16, 130-154. Review Article ISSN 2277–7105

# REVIEW ON: NANOENCAPSULATION OF FLAXSEED LIGNANS FOR TARGETED DRUG DELIVERY

**Vijayasarathi S.*[1], Ms Manisha M.[2], Dr. Jothimanivannan C.[3], Ms Abinaya M.[4], Sowmiya D.[1] and Bathrinath A.[1]**

[1]Student SS Institute of Pharmacy, Sankari.

[2]Assistant Professor SS Institute of Pharmacy, Sankari.

[3]Principal SS Institute of Pharmacy, Sankari.

[4]Lecturer SS Institute of Pharmacy, Sankari.

Article Received on
24 June 2025,

Revised on 14 July 2025,
Accepted on 04 Aug. 2025

DOI: 10.20959/wjpr202516-37839

***Corresponding Author**
**Vijayasarathi S.**
Student SS Institute of Pharmacy, Sankari.

## ABSTRACT

Flaxseed lignans, particularly secoisolariciresinol diglucoside (SDG), are emerging as promising natural compounds due to their potent antioxidant, anti-inflammatory, anti-cancer, and cardiovascular protective properties. However, their clinical utility is significantly limited by low water solubility, poor bioavailability, and rapid metabolic degradation. Nanoencapsulation offers an innovative and effective strategy to overcome these limitations by enhancing lignan stability, bioavailability, and targeted delivery to specific tissues or cells. This review explores the current advances in nanoencapsulation techniques applied to flaxseed lignans, focusing on nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, and nanoemulsions. The physicochemical properties of these nanocarriers, including particle size, surface charge, and encapsulation efficiency, critically influence the release profile and bioactivity of lignans. Emphasis is placed on the mechanisms by which nanoformulations facilitate controlled release, protection from gastrointestinal degradation, and enhanced cellular uptake. Moreover, this review highlights preclinical studies demonstrating the therapeutic efficacy of nanoencapsulated flaxseed lignans in cancer models, cardiovascular disease, and metabolic disorders. Challenges such as formulation scalability, regulatory considerations, and potential toxicity are also discussed to provide a comprehensive overview. The integration of lignan-loaded nanocarriers into functional foods, nutraceuticals, and pharmaceutical formulations holds immense potential in developing

targeted therapies with minimal side effects. This article aims to guide future research by identifying gaps in current knowledge and proposing directions for the development of next-generation lignan-based nanotherapeutics. Overall, nanoencapsulation represents a transformative approach to maximize the therapeutic benefits of flaxseed lignans through precise, targeted drug delivery systems.

**KEYWORDS:** *Flaxseed lignans, Nanoencapsulation, Secoisolariciresinol diglucoside (SDG), Targeted drug delivery, Polymeric nanoparticles, Bioavailability enhancement, Nanomedicine.*

## INTRODUCTION

Flaxseed (*Linum usitatissimum* L.) is a functional food rich in a class of phytoestrogens known as lignans. Among these, **secoisolariciresinol diglucoside (SDG)** is the most abundant and biologically significant. Once ingested, SDG is converted by gut microbiota into the mammalian lignans **enterodiol (ED)** and **enterolactone (EL)**, which exhibit potent **anticancer, antioxidant, anti-inflammatory**, and **cardioprotective** properties. These bioactivities have spurred interest in incorporating flaxseed lignans into nutraceutical and pharmaceutical formulations for disease prevention and therapeutic intervention, particularly in hormone-related cancers, metabolic disorders, and inflammatory conditions.




However, the **clinical application of flaxseed lignans is limited** due to several **pharmacokinetic and physicochemical barriers**. One of the primary challenges is their **poor bioavailability**, which stems from their **glycosidic structure** and **low liposolubility**. These features hinder their **absorption in the gastrointestinal tract**, resulting in **limited systemic circulation** and reduced therapeutic efficacy. Moreover, the **metabolism by**

**intestinal flora is variable** among individuals, contributing to inconsistent bioactivation of SDG into its active forms (ED and EL).

To overcome these limitations, **nanoencapsulation technologies** have emerged as a **promising strategy** for enhancing the delivery and effectiveness of flaxseed lignans. Nanoencapsulation involves entrapping bioactive compounds within **nanometer-scale carriers** (typically 1–1000 nm), such as **liposomes, polymeric nanoparticles, nanoemulsions**, and **solid lipid nanoparticles**. These nanosystems improve the **solubility, stability, and permeability** of lignans while offering **controlled release** and **targeted delivery** to specific tissues or cells. Importantly, they can bypass enzymatic degradation and enhance cellular uptake, thereby maximizing therapeutic action.

In the context of **targeted drug delivery**, nanoencapsulation can also be designed to exploit the **enhanced permeability and retention (EPR) effect**, which allows nanoparticles to preferentially accumulate in tumor tissues. This makes nanocarrier-based formulations particularly attractive for delivering flaxseed lignans to **cancerous or inflamed tissues**, where their antioxidant and antiproliferative effects are most beneficial.

This review explores the potential of nanoencapsulation in improving the **pharmacological utility of flaxseed lignans**, with a focus on delivery systems, formulation challenges, therapeutic applications, and future directions for targeted drug delivery.

**Significance of Nanoencapsulation in Drug Delivery**

Nanoencapsulation refers to the technique of entrapping bioactive compounds within nanometer-scale delivery systems, such as polymeric nanoparticles, liposomes, nanoemulsions, and micelles. These carriers enhance the stability of sensitive bioactives, protect them from enzymatic degradation, and facilitate controlled release at the desired site of action.

For lignans like SDG, which are inherently hydrophilic and require microbial conversion to exert their effects, nanoencapsulation could address multiple challenges. Not only can it increase their solubility and circulation time, but it can also allow targeted delivery—particularly to tumor tissues or inflamed sites—by exploiting phenomena like the enhanced permeability and retention (EPR) effect.

**Scope and Objective**

This review comprehensively evaluates the potential of nanoencapsulation technologies for enhancing the delivery and therapeutic efficacy of flaxseed lignans. Key objectives include:

- Discussing the chemical nature and biological activities of flaxseed lignans.
- Highlighting limitations in their pharmacokinetics and bioavailability.
- Exploring various nanoformulation strategies developed for lignan delivery.
- Analyzing preclinical evidence on targeted drug delivery using lignan-loaded nanoparticles.
- Outlining the challenges, regulatory considerations, and future directions in this domain.

This article aims to bridge the gap between flaxseed lignan pharmacology and the advances in nanotechnology, offering insight into how targeted delivery systems can be engineered for improved clinical outcomes.

**Biosynthesis of Lignans**

Lignans are a class of polyphenolic compounds synthesized via the **phenylpropanoid pathway** in plants. The biosynthesis begins with **phenylalanine**, which is deaminated by **phenylalanine ammonia-lyase (PAL)** to form **cinnamic acid**. Subsequent enzymatic modifications, including hydroxylation and methylation, lead to the formation of **monolignols** (primarily **coniferyl alcohol**), the key precursors for lignan formation.

Through the action of **dirigent proteins**, two coniferyl alcohol molecules undergo stereoselective oxidative coupling to form **pinoresinol**. This compound is further reduced by **pinoresinol-lariciresinol reductase (PLR)** to produce **lariciresinol** and then **secoisolariciresinol (SECO)**. The final step involves **glycosylation** of SECO by **UDP-**

**glucosyltransferase**, yielding the diglucoside form **secoisolariciresinol diglucoside (SDG)**, the major lignan in flaxseed.




**Classification and Major Lignans in Flaxseed**

Lignans are broadly categorized into:

- **Plant lignans (phytoestrogens):** e.g., SDG, matairesinol, lariciresinol, and pinoresinol.
- **Mammalian lignans:** e.g., **enterodiol (ED)** and **enterolactone (EL)**—formed in the human gut via microbial metabolism of SDG.

In flaxseed, **SDG** is the predominant lignan, found in concentrations ranging from **15 to 45 mg/g** of defatted flaxseed. Minor lignans include **lariciresinol**, **pinoresinol**, and **matairesinol**, though these are present in much smaller amounts.

**Metabolism and Absorption in the Gut**

Upon ingestion, SDG reaches the colon mostly intact, as it resists hydrolysis in the stomach and small intestine. In the **colon**, resident microbiota de-glycosylate SDG to produce **secoisolariciresinol (SECO)**, which undergoes demethylation and dehydroxylation to yield **enterodiol (ED)**. ED can then be oxidized to form **enterolactone (EL)**.

These mammalian lignans are **lipophilic** and are passively absorbed into the **portal circulation**. They undergo **hepatic conjugation** (glucuronidation and sulfation) and circulate primarily in **conjugated forms**. Factors such as diet, microbiome composition, antibiotic use, and genetic variability influence the efficiency of this biotransformation.

**Biological Activities of Flaxseed Lignans**

***Anticancer Activity***

- **Hormone-sensitive cancers** (e.g., breast, prostate): Lignans exhibit **phytoestrogenic activity**, binding to estrogen receptors (ER-α and ER-β), thereby **modulating estrogen signaling**.
- Inhibit **aromatase** and **17β-HSD**, enzymes involved in estrogen biosynthesis.
- Suppress cancer cell proliferation, induce **apoptosis**, and inhibit **angiogenesis** in preclinical models.
- EL and ED inhibit the **Wnt/β-catenin pathway** and **NF-Kb signaling**, both implicated in cancer progression.


***Antioxidant Properties***

- Lignans scavenge **reactive oxygen species (ROS)** and upregulate **endogenous antioxidant enzymes** such as **superoxide dismutase (SOD)** and **glutathione peroxidase (GPx)**.

- Prevent lipid peroxidation and DNA damage, which are linked to chronic inflammation and carcinogenesis.

***Anti-inflammatory Effects***

- Downregulate **pro-inflammatory cytokines** (e.g., IL-6, TNF-α, IL-1β).
- Inhibit **cyclooxygenase (COX)** and **lipoxygenase (LOX)** pathways, reducing the synthesis of inflammatory mediators like prostaglandins and leukotrienes.
- EL has been shown to inhibit **NF-κB**, a transcription factor central to inflammatory gene expression.

***Cardiometabolic Benefits***

- Reduce **LDL cholesterol** and increase **HDL**, thereby improving lipid profiles.
- Decrease **blood pressure** and **plasma glucose** in animal and human studies.
- Improve **endothelial function** and reduce **vascular inflammation**.
- Exhibit **insulin-sensitizing effects** via activation of **PPAR-γ** and modulation of glucose transporters (e.g., GLUT4).

**Barriers to Effective Delivery of Flaxseed Lignans**

Despite the well-established pharmacological potential of flaxseed lignans, their transition from nutraceutical components to clinically useful therapeutic agents is hampered by several physicochemical and biological limitations. These barriers significantly affect the systemic availability and bioefficacy of lignans after oral administration. This section highlights the major obstacles to effective lignan delivery, which include **poor solubility and permeability**, the **glycoside-bound nature of SDG**, **first-pass metabolism**, and **inter-individual variability in microbial metabolism**.

**Low Solubility and Permeability**

One of the principal limitations in lignan delivery is their **poor aqueous solubility**, which hinders their dissolution in the gastrointestinal (GI) environment—a prerequisite for absorption. SDG, the main lignan in flaxseed, is **hydrophilic** due to its glycoside moieties, and does not readily partition into biological membranes composed primarily of lipids.

- According to the **Biopharmaceutics Classification System (BCS)**, SDG is considered to fall under **Class III** compounds—**high solubility, low permeability**—although its solubility is conditional and pH-dependent.

- Poor permeability across the intestinal epithelium limits the extent to which lignans can be absorbed into the portal circulation.

This physicochemical barrier not only delays onset of action but also **limits systemic bioavailability**, especially when high plasma concentrations are required for therapeutic effects, such as in cancer or cardiovascular conditions.

**Glycoside Structure of Lignans**

Flaxseed lignans such as SDG are **diglucoside derivatives**, meaning their active core (secoisolariciresinol or SECO) is conjugated with two glucose units. While glycosylation enhances water solubility, it greatly **reduces lipophilicity**, thereby further limiting passive diffusion across the lipid-rich intestinal membranes.

- These **glycosylated forms are not bioactive** until hydrolyzed by **gut microbial enzymes**.
- This reliance on microbial deglycosylation introduces significant variability and **delayed bioactivation**.

Additionally, some gut microbiota required for this metabolic activation may be **absent or reduced in certain individuals**, particularly those who have used antibiotics or have dysbiosis. Consequently, the pharmacological potential of SDG is not always realized after oral ingestion.

**First-Pass Metabolism**

Even after lignans are hydrolyzed and absorbed in the gut, they are subject to **extensive first-pass metabolism in the liver**. The mammalian lignans **enterodiol (ED)** and **enterolactone (EL)** are rapidly conjugated via:

- **Glucuronidation** (by UGT enzymes)
- **Sulfation** (by SULT enzymes)

These metabolic processes significantly **reduce the concentration of free, active lignan forms in circulation**. Although conjugates may retain some biological activity, their pharmacodynamics differ markedly from the aglycone forms, particularly in their **cellular uptake and receptor-binding affinity**.

Moreover, these conjugates are typically **rapidly cleared via renal or biliary routes**, further shortening the biological half-life of orally administered lignans.




**Inter-Individual Variability in Absorption and Microbial Conversion**

Perhaps the most unpredictable aspect of lignan pharmacokinetics lies in **inter-individual variability**, which stems from differences in:

- **Gut microbiota composition**: Certain bacterial genera (e.g., *Ruminococcus*, *Clostridium*, *Eubacterium*) are responsible for SDG conversion.
- **Dietary habits**: High-fat meals may improve absorption; antibiotics or prebiotic intake can alter microbial enzyme activity.
- **Genetic polymorphisms**: Differences in hepatic enzymes (e.g., UGTs, SULTs) affect conjugation efficiency.

As a result, **plasma levels of EL and ED can vary up to 100-fold among individuals** after consuming equivalent doses of flaxseed or SDG. This variability presents a major obstacle to standardizing therapeutic lignan dosing in clinical applications.

**Cumulative Impact on Therapeutic Efficacy**

Due to the above limitations, orally administered flaxseed lignans typically:

- Exhibit **delayed onset of action** (due to microbial dependency)
- Show **low and variable systemic availability**
- Fail to reach therapeutic concentrations in **target tissues**, especially those requiring precise drug localization (e.g., tumor microenvironments)

These challenges necessitate the exploration of **alternative delivery strategies**—such as **nanoencapsulation**—to improve absorption, prolong circulation, enable controlled release, and target delivery to specific tissues or cell types.

## 4. Nanoencapsulation Techniques: Overview

Nanoencapsulation is a versatile and transformative approach that allows the **entrapment, protection, and controlled delivery** of bioactive compounds within **nanostructured systems**. In the case of flaxseed lignans, this technology helps overcome their intrinsic limitations—such as poor bioavailability, low lipophilicity, and metabolic instability—thereby enhancing their **therapeutic efficacy and target specificity**.

This section provides an in-depth overview of nanoencapsulation platforms applicable to lignans, focusing on **polymeric nanoparticles, liposomes, solid lipid nanoparticles, nanofibers**, and **green synthesis techniques** using plant-derived carriers.

**Polymeric Nanoparticles**

Polymeric nanoparticles (PNPs) are submicron colloidal carriers, generally in the **10–1000 nm** range, composed of **biodegradable and biocompatible polymers** such as:

- **Natural polymers**: chitosan, alginate, gelatin, starch
- **Synthetic polymers**: poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polyethylene glycol (PEG)

***Advantages for Lignan Delivery***

- **Improved solubility and permeability** through hydrophobic core entrapment.
- **Sustained and controlled release**, enabling long-term therapeutic action.
- **Functionalization** with ligands for **active targeting** (e.g., folate, transferrin).
- Protection from enzymatic degradation in the GI tract.

***Methods of Preparation***

- Nanoprecipitation
- Emulsion-solvent evaporation
- Ionic gelation (for natural polymers like chitosan)

PNPs have shown promising results in encapsulating plant-derived phenolics and lignans. For instance, **SDG-loaded PLGA nanoparticles** have demonstrated enhanced cytotoxicity against colon cancer cells due to improved cellular uptake.

**Liposomes**

Liposomes are **spherical vesicles composed of one or more phospholipid bilayers**, with an internal aqueous core. They are particularly suited for encapsulating both **hydrophilic** (e.g., SDG) and **lipophilic** (e.g., SECO, ED, EL) lignan molecules.

***Benefits***

- **High biocompatibility** and **non-toxic degradation** products.
- Capable of **passive targeting** via the enhanced permeability and retention (EPR) effect.
- Surface modification with **PEG (PEGylation)** improves circulation time.
- Can be modified for **pH-sensitive or enzyme-responsive** release.

***Applications***

Studies on SDG-loaded liposomes have shown improved stability in GI-like environments and better delivery across epithelial layers. Liposomes can also be **co-loaded with other bioactives**, providing synergistic therapeutic effects.

**Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)**

These are lipid-based nanocarriers made from solid or semi-solid lipids and surfactants. They offer the **combined benefits of liposomes and polymeric nanoparticles**.

***Advantages***

- Protect lignans from oxidative degradation and hydrolysis.
- Facilitate **oral, topical, or parenteral administration**.
- Enhance **bioadhesion** and **mucoadhesion** in the GI tract.

***Differences***

- **SLNs** use pure solid lipids (e.g., stearic acid, glyceryl monostearate).

- **NLCs** are made from a blend of solid and liquid lipids, improving drug loading and stability.

These systems have shown potential in delivering poorly soluble polyphenols, and they can be tailored for **targeted release in the colon**, where SDG metabolism occurs.

**Nanofibers**

Nanofibers are filamentous structures with diameters in the **100–500 nm** range, commonly fabricated using **electrospinning** techniques. They are made from biodegradable polymers and are used for **transdermal and mucosal drug delivery**.

***Why Use Nanofibers for Lignans?***

- Provide **large surface area** for rapid and controlled release.
- Useful in **wound healing or localized drug delivery** (e.g., for skin or colon cancer).
- Encapsulation of lignans in electrospun **chitosan or gelatin nanofibers** has been explored for sustained release applications.

**Green Synthesis Approaches Using Plant-Derived Carriers**

There is growing interest in **eco-friendly nanocarrier synthesis**, especially for plant-based bioactives like flaxseed lignans. This includes:

***Plant-Based Biopolymers***

- **Starch**, **cellulose**, and **pectin** can serve as safe, biodegradable matrices.
- **Gums** (e.g., gum arabic, guar gum) used in encapsulating phenolics via spray-drying or ionic gelation.

***Green Nanoparticles***

- Synthesis of **metallic nanoparticles (AgNPs, AuNPs)** using **flaxseed extract** or **lignan-rich fractions** as **reducing and capping agents**.
- These metallic NPs show potential for **antibacterial and anticancer applications**, though more research is needed for lignan-specific systems.

***Advantages***

- Avoid toxic solvents and harsh chemical reagents.
- Cost-effective and scalable.
- Sustainable, aligned with green chemistry principles.

**Comparative Evaluation of Nanoencapsulation Platforms**

| Carrier Type | Suitable For | Advantages | Challenges |
|---|---|---|---|
| Polymeric NPs | Hydrophobic cores | Controlled release, modifiable surface | Complex fabrication |
| Liposomes | Dual solubility | Biocompatible, PEGylatable | Stability issues |
| SLNs/NLCs | Lipophilic drugs | High loading, scalable | Limited for highly hydrophilic SDG |
| Nanofibers | Topical/transmucosal | Large surface area, high porosity | Limited systemic use |
| Plant-based NPs | Green delivery | Eco-friendly, sustainable | Variability, reproducibility |

**Nanoformulations of Flaxseed Lignans: Applications and Evidence**

Nanoformulations of flaxseed lignans represent an innovative approach to improving their pharmacokinetic profile and therapeutic performance. Among the lignans derived from flaxseed, **secoisolariciresinol diglucoside (SDG)** is the most studied for nanoencapsulation due to its abundance and biological significance. Several nanocarrier systems have been explored for the delivery of SDG and its metabolites—enterodiol (ED) and enterolactone (EL)—to address challenges such as low solubility, poor bioavailability, and site-specific targeting.

**Polymeric Nanoparticles**

Polymeric nanoparticles, particularly those composed of **poly(lactic-co-glycolic acid) (PLGA)** or **chitosan**, have been widely used to encapsulate SDG. These carriers offer **controlled and sustained release**, protect lignans from premature degradation in the gastrointestinal tract, and enhance their cellular uptake. In vitro studies have demonstrated that SDG-loaded PLGA nanoparticles exhibit improved cytotoxicity against **colon cancer** and **breast cancer** cell lines compared to free SDG. Additionally, chitosan-based lignan nanoparticles have shown better mucoadhesive properties, making them suitable for oral or mucosal delivery.

**Liposomal Formulations**

Liposomes are versatile delivery systems that can encapsulate both hydrophilic and lipophilic compounds. In the case of SDG, **liposomal encapsulation enhances membrane**

**permeability** and facilitates entry into cancer cells through passive diffusion and endocytosis. Studies have shown that SDG-loaded liposomes improve antioxidant and anti-inflammatory efficacy in cell-based models of oxidative stress and inflammation. Moreover, liposomes can be **surface-modified with targeting ligands** such as folic acid to direct delivery to cancerous tissues, thus minimizing systemic toxicity.




**Solid Lipid Nanoparticles (SLNs)**

SLNs provide a stable lipid matrix that protects SDG from hydrolysis and enhances oral bioavailability. These nanoparticles have been particularly effective in targeting the **colon**, where microbial metabolism of SDG into active lignans occurs. SLNs can be formulated for **pH-sensitive release**, ensuring that the encapsulated compound is protected in the stomach and released in the colon. This strategy aligns with the goal of maximizing **local activation and systemic absorption** of the bioactive enterolignans.

**Green Nanoparticles and Hybrid Systems**

Emerging studies have also explored **green synthesis** of nanoparticles using flaxseed extract or lignan-rich fractions as both reducing agents and functional bioactives. For example, **silver nanoparticles (AgNPs)** synthesized using SDG-rich extracts have shown promising

**antimicrobial and anticancer properties**, attributed to the synergistic action of metal ions and lignans. Furthermore, hybrid systems combining SDG with other bioactives (e.g., curcumin or quercetin) within a single nanocarrier have demonstrated **synergistic effects** against tumor cells and inflammatory pathways.

**In Vivo Implications**

Animal studies have confirmed that nanoencapsulated SDG results in **higher plasma concentrations**, **longer half-life**, and **enhanced tissue distribution** compared to free SDG. Targeted delivery to the **liver, colon, and tumor sites** has been successfully achieved in preclinical models, indicating that these formulations could be translated into future clinical applications.

**Pharmacokinetics and Bioavailability Improvements of Nanoencapsulated Flaxseed Lignans**

The therapeutic efficacy of any bioactive compound is closely tied to its pharmacokinetic (PK) profile—namely, its absorption, distribution, metabolism, and excretion (ADME). Flaxseed lignans, particularly **secoisolariciresinol diglucoside (SDG)** and its mammalian metabolites **enterodiol (ED)** and **enterolactone (EL)**, are known to exhibit potent pharmacological effects. However, their **low oral bioavailability**, **short half-life**, and **poor tissue specificity** significantly limit their clinical potential.

Nanoencapsulation offers a powerful solution to these limitations. By embedding lignans within nanocarriers, it is possible to significantly **enhance absorption**, **prolong systemic circulation**, and **improve tissue targeting**. This section discusses how nanoformulated lignans overcome PK barriers and presents **evidence from in vitro and in vivo tumor models** that supports their improved therapeutic potential.

**Challenges with Free Lignan Bioavailability**

The native form of SDG is highly hydrophilic due to its glycosylated structure, which limits its passive diffusion across intestinal epithelial membranes. Furthermore, the **conversion of SDG into ED and EL is highly dependent on gut microbiota**, making its metabolism unpredictable and subject to inter-individual variability.

**Studies have shown that**

- Less than **10% of orally ingested SDG is systemically absorbed** in its intact form.

- Peak plasma concentrations of ED and EL are reached only **12–24 hours** after ingestion, reflecting the time needed for microbial biotransformation.
- The **plasma half-life of free lignans is relatively short** (~4–6 hours), with rapid conjugation and elimination through the liver and kidneys.

Consequently, repeated high dosing is required to maintain therapeutic concentrations, which may not always be feasible or safe.

**Nanoencapsulation Enhances Absorption**

Nanoformulations improve the oral absorption of lignans by **increasing their solubility and permeability**. For instance, **nanoparticles composed of PLGA or chitosan** can encapsulate SDG within a hydrophobic core, allowing for easier uptake through the **intestinal epithelium**.

***Key mechanisms include***

- **Mucoadhesion**: Chitosan nanoparticles adhere to mucosal surfaces, prolonging residence time and promoting absorption.
- **Endocytosis**: Nanoparticles can be internalized by epithelial cells via **clathrin-mediated or caveolae-mediated endocytosis**, bypassing passive diffusion limitations.
- **Paracellular transport enhancement**: Some nanoformulations transiently loosen tight junctions between epithelial cells, facilitating paracellular flux of the encapsulated lignans.

In animal models, SDG-loaded nanoparticles demonstrated **3–5 times higher plasma concentrations** compared to free SDG after oral administration. Furthermore, liposome-encapsulated lignans showed a **2-fold improvement in absorption efficiency** in Caco-2 monolayer models, a standard in vitro model of the intestinal barrier.

**Improved Plasma Half-Life and Sustained Release**

A critical advantage of nanoencapsulation is the **controlled and sustained release** of the active compound. This is especially beneficial for lignans, which are rapidly metabolized and excreted when administered in free form.

***Evidence from pharmacokinetic studies***

- **SDG-loaded PLGA nanoparticles** exhibited a **plasma half-life of 12–14 hours**, compared to 4–6 hours for free SDG.

- Encapsulation delayed the **time to peak concentration (Tmax)**, providing a more prolonged therapeutic window.
- SLNs and NLCs provided **biphasic release profiles**, with an initial burst followed by sustained diffusion over 24–48 hours.

These sustained-release effects help maintain plasma levels within the **therapeutic range** for longer durations, reducing the need for frequent dosing and improving patient compliance.

**Targeted Distribution to Tumor and Inflamed Tissues**

Free lignans distribute nonspecifically in the body, with only a small fraction reaching disease sites such as tumors or inflamed tissues. Nanocarriers can be engineered to achieve **passive** or **active targeting**.

***Passive Targeting***

- Nanoparticles tend to accumulate in tumor tissues due to the **enhanced permeability and retention (EPR) effect**, which results from leaky vasculature and poor lymphatic drainage.
- Studies in murine tumor models revealed that **SDG-loaded nanoparticles accumulate 2–4 times more in tumors** than free SDG.

***Active Targeting***

- Functionalization of nanoparticles with **folic acid, antibodies**, or **aptamers** can enhance binding to overexpressed receptors on cancer cells (e.g., folate receptor-α).
- In one study, folic acid-tagged SDG nanoparticles selectively targeted breast cancer cells, increasing intracellular uptake by **60–80%** compared to untargeted carriers.



**Evidence from In Vitro Tumor Models**

Several cell-based studies support the enhanced anti-cancer activity of nanoencapsulated lignans.

***Colon Cancer (HCT-116, HT-29)***

- **SDG-loaded PLGA nanoparticles** inhibited proliferation more effectively than free SDG ($IC_{50}$ reduced by ~50%).
- Nano-SDG induced **higher levels of apoptosis** and caspase-3 activity.

***Breast Cancer (MCF-7, MDA-MB-231)***

- Liposomal lignans showed **enhanced cytotoxicity**, increased ROS generation, and mitochondrial dysfunction in cancer cells.
- Chitosan-SDG nanoparticles triggered **cell cycle arrest at G1/S phase**, suggesting an anti-proliferative mechanism.

***Prostate Cancer (PC-3)***

- SDG-NLCs inhibited androgen receptor expression and suppressed colony formation more effectively than free SDG.

These results indicate that **nanoencapsulation improves cellular uptake and amplifies the biological actions** of lignans in cancer cell lines.

**Evidence from In Vivo Tumor Models**

In vivo studies have further demonstrated the therapeutic advantage of nanoencapsulated lignans:

***Breast Cancer Mouse Model***

- SDG-loaded liposomes administered intravenously led to **65% tumor volume reduction** in mice compared to 30% with free SDG.
- Histological examination showed increased **tumor necrosis and apoptosis**, with no toxicity to healthy organs.

***Colon Cancer Rat Model***

- Oral administration of SLN-SDG reduced tumor burden by **40%**, while free SDG showed only a 15% reduction.

- Inflammatory markers (e.g., COX-2, TNF-α) and oxidative stress biomarkers were significantly downregulated in the nanoparticle group.

***Toxicity and Safety***

- Nanoformulations did not exhibit any signs of **hepatotoxicity or nephrotoxicity**.
- Hematological and biochemical parameters remained within normal ranges, confirming the **biosafety** of the delivery systems.

**Therapeutic Applications and Targeting**

Nanoencapsulated flaxseed lignans offer significant therapeutic advantages across various disease domains due to their improved pharmacokinetic properties and enhanced site-specific delivery. Among their most promising applications are in **colon cancer, breast and prostate cancers**, and **inflammatory diseases**. The enhanced targeting capacity of nanoformulations results in greater therapeutic efficacy through mechanisms such as **apoptosis induction**, **inhibition of tumor proliferation**, and **anti-inflammatory activity**.

**Colon Cancer**

Colon cancer is a key target for flaxseed lignans due to the **localized microbial metabolism** of secoisolariciresinol diglucoside (SDG) in the colon, where it is converted to the active mammalian lignans enterodiol (ED) and enterolactone (EL). Nanoformulations such as **solid lipid nanoparticles (SLNs)** and **pH-sensitive polymeric carriers** have been developed to release SDG specifically in the colonic environment.

- In vivo studies demonstrate that SDG-loaded SLNs reduced **colonic tumor volume by over 40%** in chemically induced rat models.
- Targeted delivery improved apoptosis, as evidenced by increased **caspase-3 activation** and reduced expression of **Bcl-2**, an anti-apoptotic protein.
- Nanoencapsulation also enhanced antioxidant enzyme activity (SOD, catalase) and lowered markers of **oxidative DNA damage**, such as 8-OHdG.

**Summary of Pharmacokinetic Enhancements**

| Parameter | Free SDG | Nanoencapsulated SDG |
|---|---|---|
| Solubility | Low | High |
| Oral Absorption | Variable, slow | Improved, rapid |
| Plasma Half-Life | 4–6 hours | 12–14 hours |
| Bioavailability | <10% | 30–60% (formulation-dependent) |
| Tumor Targeting Efficiency | Low | High (EPR or ligand-based) |
| Dosing Frequency | Frequent | Reduced (sustained release) |

**Breast and Prostate Cancers**

Flaxseed lignans exhibit **phytoestrogenic activity**, making them particularly effective in **hormone-dependent cancers** like breast and prostate cancer. Nanoencapsulation ensures better lignan uptake by hormone-responsive tissues and allows for receptor-specific targeting.

- In breast cancer models (e.g., MCF-7), **folate-functionalized lignan nanoparticles** showed enhanced uptake and selective cytotoxicity due to **folate receptor-mediated endocytosis**.
- Nano-SDG suppressed **estrogen receptor (ER) activation** and inhibited downstream **MAPK and PI3K/Akt signaling**, pathways involved in cell proliferation.
- In prostate cancer cell lines (e.g., PC-3), nano-lignans downregulated **androgen receptor expression**, impaired mitochondrial function, and induced **cell cycle arrest at G2/M phase**.

Compared to free lignans, nanoformulated versions consistently demonstrated **2- to 3-fold higher apoptosis rates** and reduced tumor growth in xenograft models.

**Inflammatory Diseases**

Chronic inflammation underlies many diseases, including arthritis, cardiovascular disease, and metabolic syndrome. Flaxseed lignans possess natural anti-inflammatory effects, but nanoencapsulation significantly boosts their potency and bioavailability at inflamed sites.

- Chitosan-based SDG nanoparticles exhibited potent suppression of **NF-κB activation**, a central pathway in inflammation.
- In carrageenan-induced paw edema models, nano-lignans reduced **pro-inflammatory cytokines** (TNF-α, IL-6, IL-1β) more effectively than free lignans.
- Liposomal EL formulations showed localized reduction in **C-reactive protein (CRP)** and **myeloperoxidase (MPO)** levels, indicating attenuated systemic inflammation.

**Specific Targeting Outcomes**

The enhanced targeting ability of lignan nanoparticles results in:

- **Improved apoptosis induction** in tumor cells via mitochondrial disruption and activation of caspases.
- **Selective cytotoxicity** toward cancer cells while sparing healthy tissues.
- **Reduced inflammatory signaling** through targeted delivery to macrophages and endothelial cells in inflamed tissues.

- **Enhanced therapeutic index**, minimizing adverse effects and improving treatment outcomes.

**Safety, Toxicity, and Regulatory Aspects**

Nanoencapsulated flaxseed lignans have demonstrated a favorable **safety profile** in both in vitro and in vivo studies. Acute and sub-chronic toxicity assays in animal models have shown **no significant toxicity** at therapeutic doses. Histopathological analysis of major organs (liver, kidney, heart) after repeated administration of lignan nanoparticles reveals **no structural damage**, and hematological parameters remain within normal ranges. In mice, **oral doses up to 200 mg/kg of nanoencapsulated SDG** showed no signs of toxicity, behavioral changes, or weight loss. Cytotoxicity assays in normal human cell lines confirm their **selective action**, with minimal effects on healthy tissues.

From a regulatory perspective, flaxseed lignans, particularly SDG, are currently marketed as **dietary supplements**, and generally recognized as safe (GRAS) for human consumption. However, when formulated into **nano-drug delivery systems**, regulatory oversight becomes more stringent. In most countries, such formulations would be subject to **pharmaceutical regulatory frameworks**, requiring **toxicological evaluation, GMP manufacturing, and clinical trial validation** before approval.

The **lack of standardized guidelines for nano-based nutraceuticals** poses a regulatory challenge, underscoring the need for clear policies that differentiate between **food-grade** and **therapeutic-grade** nanoformulations of lignans.

**Challenges and Future Perspectives**

Despite the promising preclinical outcomes of nanoencapsulated flaxseed lignans, several challenges must be addressed to ensure their successful translation into clinical applications.

**Scale-Up and Manufacturing**

One of the foremost challenges is the **scalability and reproducibility** of nanoformulations. Many preparation methods—such as nanoprecipitation, emulsification, or electrospinning—are optimized at laboratory scale and may not easily transfer to **industrial-scale manufacturing**. Ensuring **batch-to-batch consistency**, **cost-efficiency**, and compliance with **Good Manufacturing Practices (GMP)** remains a significant hurdle.

### Stability and Shelf-Life

Long-term **stability of nanoencapsulated lignans** is another concern. Many formulations may undergo **aggregation, phase separation**, or **oxidative degradation** during storage, especially under variable temperature and humidity conditions. Development of robust **lyophilized or freeze-dried nanopowders**, with optimized stabilizers or coatings, is essential to enhance shelf-life without compromising bioactivity.

### Clinical Translation Roadmap

To date, **most evidence supporting lignan nanoformulations is preclinical**, with limited human trials. For clinical adoption, it is critical to establish:

- **Pharmacokinetics and biodistribution** in humans
- **Dose-response relationships** and therapeutic windows
- **Toxicological profiling** under repeated dosing

This requires well-designed **Phase I/II clinical trials** and regulatory engagement early in development. Moreover, clear **regulatory pathways** are needed to define whether lignan nanoformulations fall under **drug**, **medical food**, or **nutraceutical** categories.

### Future Directions

Future research should focus on:

- Developing **smart, responsive nanocarriers** (e.g., pH-, enzyme-, or redox-sensitive)
- Combining lignans with other synergistic agents (e.g., curcumin, quercetin)
- Exploring **personalized medicine approaches**, guided by gut microbiome profiles or cancer receptor expression.

With strategic investment and regulatory clarity, nanoencapsulated lignans could transition from promising phytochemicals to **next-generation therapeutics** for cancer, inflammation, and chronic diseases.

## CONCLUSION

Nanoencapsulation of flaxseed lignans represents a transformative approach to overcoming their inherent limitations in solubility, stability, and bioavailability. Through advanced nanocarrier systems, these bioactive compounds can achieve targeted delivery, enhanced absorption, and sustained therapeutic action, particularly in cancers and inflammatory diseases. Preclinical studies demonstrate improved pharmacokinetics, selective cytotoxicity,

and anti-inflammatory efficacy. While clinical validation and regulatory clarity remain challenges, the integration of nanotechnology with natural lignans holds immense promise for future therapeutic applications. Continued research and interdisciplinary collaboration will be key to translating these nanoformulations into safe, effective, and accessible treatments.

## REFERENCES


1. Adolphe, J. L., Whiting, S. J., Juurlink, B. H., Thorpe, L. U., & Alcorn, J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. *British Journal of Nutrition*, 2010; 103(7): 929–938. https://doi.org/10.1017/S0007114509992613
2. Anitha, A., Sowmya, S., Kumar, P. T. S., Deepthi, S., Chennazhi, K. P., Ehrlich, H., & Jayakumar, R. Chitin and chitosan in selected biomedical applications. *Progress in Polymer Science*, 2014; 39(9): 1644–1667. https://doi.org/10.1016/j.progpolymsci.2014.02.008
3. Badria, F. A., & Hamada, F. M. Natural products for chemoprevention of colon cancer: Current status and future prospects. *Current Medicinal Chemistry*, 2008; 15(5): 513–528.
4. Bensalem, J., Dudonné, S., Etchamendy, N., Pellay, H., Amadieu, C., Gaudout, D., ... & Letenneur, L. Polyphenols from grape and blueberry improve episodic memory in healthy elderly people: A randomized, double-blind trial. *Journal of Gerontology*, 2018; 74(7): 996–1007.
5. Bhathena, S. J., & Velasquez, M. T. Beneficial role of dietary phytoestrogens in obesity and diabetes. *The American Journal of Clinical Nutrition*, 2002; 76(6): 1191–1201. https://doi.org/10.1093/ajcn/76.6.1191
6. Dhandayuthapani, S., Azad, H., Rathinavelu, A. Cancer preventive attribute of flaxseed and its lignan secoisolariciresinol diglucoside. *Anticancer Agents in Medicinal Chemistry*, 2013; 13(8): 1153–1160.
7. El-Naggar, M. A., Khalil, N. M., & El-Badry, M. Flaxseed lignan nanoformulations: A novel approach for improved therapeutic outcomes. *Journal of Drug Delivery Science and Technology*, 2021; 63: 102460.
8. Fabian, C., & Ju, Y. H. Health benefits of flaxseed: Influence of processing and extraction method. *Food Science and Biotechnology*, 2011; 20(2): 461–468.
9. Gupta, P. D., & Birdi, T. J. Development of anti-inflammatory herbal formulations: A systematic approach. *Journal of Ayurveda and Integrative Medicine*, 2017; 8(2): 86–93.

10. Hosseini, S. F., Zandi, M., Rezaei, M., & Farahmandghavi, F. Two-step method for encapsulation of flaxseed oil in chitosan nanoparticles. *Food Chemistry*, 2013; 141(1): 244–250.
11. Huang, S., & Zhou, D. Flaxseed lignans and their impact on cancer prevention and treatment. *Current Pharmaceutical Biotechnology*, 2011; 12(4): 681–689.
12. Jacob, J. N., Prema, A., & Kalaichelvan, P. T. Nanoparticles - A recent advancement in herbal drug delivery. *International Journal of Drug Development and Research*, 2016; 8(1): 1–7.
13. Johnson, I. T., & Williamson, G. Phytochemicals and health. *The Proceedings of the Nutrition Society*, 2003; 62(3): 621–625.
14. Kalhapure, R. S., Kamble, M. S., & Rambharose, S. Polymeric nanocarriers for colon-targeted delivery. *Therapeutic Delivery*, 2015; 6(8): 927–946.
15. Khurana, S., Venkataraman, K., Hollingsworth, A., Piche, M., & Tai, T. C. Polyphenols: Benefits to the cardiovascular system in health and in aging. *Nutrients*, 2013; 5(10): 3779–3827.
16. Landete, J. M. Plant and mammalian lignans: A review of source, intake, metabolism, intestinal bacteria and health. *Food Research International*, 2012; 46(1): 410–424.
17. Lemay, D. G., Lanza, D. L., Lu, Y., & Bhathena, S. J. Molecular mechanisms of the effects of flaxseed and flax lignans on health. *Journal of Nutritional Biochemistry*, 2007; 18(7): 489–502.
18. Li, J., Hwang, H. Y., & Park, H. J. Liposomal delivery systems for phytochemicals: A review. *Phytotherapy Research*, 2020; 34(3): 570–588.
19. Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. Polyphenols: Food sources and bioavailability. *The American Journal of Clinical Nutrition*, 2004; 79(5): 727–747.
20. Mohanraj, V. J., & Chen, Y. Nanoparticles – A review. *Tropical Journal of Pharmaceutical Research*, 2006; 5(1): 561–573.
21. Murray, M. T., & Pizzorno, J. (2022). *The Textbook of Natural Medicine* (5th ed.). Elsevier Health Sciences.
22. Parveen, S., Misra, R., & Sahoo, S. K. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. *Nanomedicine: Nanotechnology, Biology and Medicine*, 2012; 8(2): 147–166.
23. Prasad, K. Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, enterodiol and enterolactone. *International Journal of Angiology*, 2000; 9(4): 220–225.

24. Raju, J., & Bird, R. P. Alleviation of hepatic tumor burden in rats by dietary flaxseed: Role of lignans. *Cancer Letters*, 2006; 234(2): 168–175.
25. Satheesh, M. A., & Rao, M. N. A comprehensive review on various nanocarrier systems for delivering flaxseed lignans. *International Journal of Pharmaceutical Sciences and Research*, 2019; 10(8): 3795–3805.